DEAD/H-box helicase 11 like 5 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DDX11L5 profile across patient tissues and cancer cell-line models. DDX11L5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DDX11L5 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, DDX11L5 RNA expression shows 7,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LUSC, and TGCT as cancer lineages where DDX11L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX11L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX11L5 survival associations across molecular data types. DDX11L5 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX11L5 RNA expression–survival associations across cancer types. High DDX11L5 expression shows unfavorable associations in COAD, READ, LIHC, LUAD and UVM, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for DDX11L5 RNA expression.
This table summarizes DDX11L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DDX11L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX11L5 shows higher tumor expression in LUSC. The LUSC box plot shows higher DDX11L5 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .043).
This table shows molecular features associated with DDX11L5 in patient tissues and cancer cell lines. In patient samples, DDX11L5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
